Abstract
Background
A comparison of chemotherapy with PP (cisplatin, CDDP; and peplomycin, PEP) and TPP (4′-O-tetrahydropyranyladriamycin: THP-ADM, CDDP and PEP) in the treatment of oral cancer.
Methods
This study included 159 out of 199 patients who had visited the collaborating institutions' hospitals, and who had been registered in the Examination Meeting of Chemotherapy for Oral Cancer during the 2-year period from June 1990 to May 1992. Ninety-seven patients underwent PP therapy and 62 underwent TPP therapy. In PP intravenous infusion therapy, 60–80 mg of CDDP per m2 was administered on day 1, followed by infusion of 5–7.5 mg of PEP per m2 from day 2 until day 6. In the PP intra-arterial infusion therapy, in which the drugs were infused in a retrograde fashion into the superficial temporal artery, 50–70 mg of CDDP per m2 was infused on day 1, followed by infusion of 5 mg of PEP per m2 from day 2 until day 6. In both the intravenous and intra-arterial TPP therapy regimens, 20 mg of THP-ADM per m2 was infused on day 1, followed by infusion of 50 mg of CDDP per m2 on day 2, and infusion of 5 mg of PEP per m2 from day 3 until day 7.
Results
The response rate of TPP therapy was 64.5%, which was not significantly different from the 53.6% obtained with PP therapy. However, the complete response (CR) rate with TPP therapy was 22.6%, significantly higher than the 9.3% with PP therapy. The response rate of TPP intra-arterial infusion therapy was particularly high (92.3%), and significantly higher than that of PP therapy. The response rate of TPP intra-arterial infusion therapy was very high (100.0%) in stage I and II patients and in primary cancers of the tongue, gingiva, buccal mucosa, and hard palate. The toxicity of TPP and PP therapies resulted in a high incidence of nausea/vomiting and anorexia. Skin disorders and epilation were observed at high rates with TPP therapy, and incidences were particularly high (100.0%) in the TPP intra-arterial infusion therapy group. The incidence of leukopenia was high in patients treated with TPP therapy but was not severe.
Conclusion
The results of this study suggest that TPP therapy is more effective than PP therapy in the treatment of oral cavity cancer. Although TPP therapy was associated with skin abnormalities, alopecia, and leukopenia as side effects, there was no influence on subsequent treatment. TPP intra-arterial infusion therapy appears promising in the treatment of oral cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in E. coli by electrolysis products from a platinum electrode. Nature 1965;205:698–699.
Wiltshaw E, Kroner T. Phase II study of cisdichlorodiammineplatinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 1976;60:55–62.
Nerrin CE. Treatment of genitourinary tumors with cisdichlorodiammine-platinum(II): experience in 250 patients. Cancer Treat Rep 1979;63:1579–1584.
Hall DJ, Diasio R, Goplerud DR. Cis-platinum in gynecologic cancer. Amer J Obsetet Gyn 1981;141:305–308.
Rossof AH, Bearden JD, Coltman A, Jr. Phase evaluation of cis-diamine-dichloro-platinum (II) in lung cancer. Cancer Treat Rep 1976;60:1679–1685.
Wittes RE, Brescia F, Young CW, Magill GB, Krakoff IH. Combination chemotherapy with cis-diamine-dichloroplatinum (II) and bleomycin in tumor of the head and neck. Oncology 1975;32:202–207.
Creagan ET, Fleming TR, Edomonson JH. Cyclophosphamide, adriamycin and cis-diamine-dichloroplatinum (II) in the treatment of patients with advanced head and neck cancer. Cancer 1981;47:240–244.
Evin TJ, Weichselbaum R, Miller D, Meshad M, Posner M, Fabian R. Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin and methotrexate. Cancer Treat Rep 1981;65:787–791.
Inuyama Y, Mashino S, Fujii M, Tanaka Z, Takaoka T, Kohno N, Horiuchi M, Otsuki J. Combined chemotherapy with cisplatin and peplomycin in head and neck cancer. Jpn J Cancer Chemother 1983;10:97–103.
Kurita S, Kiyokawa K, Ohkubo H, Kawaguchi Z, Tateishi S, Matsuoka H, Hirano M. Histological effects of cis-platinum, peplomycin induction chemotherapy for head and neck carcinomas. J Jpn Soc Cancer Ther 1985;20:2126–2134.
Kaneda T, Kawabe Y. Primary clinical effects of chemotherapy mainly with cisplatin, peplomycin (PP therapy) research in Tokai district. J Jpn Soc Cancer Ther 1987;22:1385–1398.
Tohnai I, Kawabe Y, Nakashima T, Yamagiwa M, Suzuki T, Mizuno A, Mineda H. Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer. J Jpn Soc Cancer Ther 1990;25:2567–2578.
Hashimoto K, Shioda S, Teshima T, Shioiri S, Kaneda T, Iizuka T, Nukata J, Takada K, Hayatsu Y, Ozeki S, Kawashima K. Primary clinical effects of chemotherapy mainly with cisplatin, peplomycin (PP therapy) for oral cancer. The multi-institutional joint research in oral surgery, Part 1. J Jpn Soc Cancer Ther 1993;28:1677–1689.
Umezawa H, Takahashi Y, Kinoshita M, Naganaw H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiotics 1979;32:1082–1084.
Hurue N, Hara Y, Imamura Y, Kimura T, Koyama Y, Kurihara M, Nakao I, Ogawa K, Sakai Y, Sakuma A, Tominaga Y, Yokayama M. A judgment of direct effects of chemotherapy for solid carcinoma. J Jpn Soc Cancer Ther 1986;21:929–942.
Lippman AJ, Helson C, Helson L, Krakoff IH. Clinical trial of cis-dichloro-diammine-platinum (II) (NSC-119875). Cancer Chemother Rep 1973;57:191–200.
Wittes RE, Cvitkovic E, Shah J, Gerold FF, Strong EW. Cis-diamine-dichloroplatinum (II) (CDDP) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 1977;61:354–366.
Masuno S. Effect of the combination of cisplatin and peplomycin on Ehrilich ascites carcinoma and on head and neck squamous cell carcinoma transplanted to nude mice. J Otolaryngol Jpn 1985;88:502–511.
Ekimoto H, Akikawa M, Takahashi K. Fundamental studies on combination chemotherapy of cisplatin with peplomycin against human squamous cell carcinomas in nude mice. Jpn J Cancer Chemother 1985;12:70–76.
Fujii M. Fundamental study on the combination therapy of cisplatin and peplomycin. J Otolaryngol Jpn 1985;88:512–519.
Hosoda H. Fundamental studies on chemotherapy 4′-O-tetrahydropyranyl-adriamycin, cisplatin and peplomycin against Ehlich ascites carcinoma. Keio Igaku 1986;63:635–644.
Asai M. Combined chemotherapy of CDDP-THP-PEP for squamous cell carcinoma of the head and neck. Jpn J Cancer Clin 1991;37:716–720.
Hashimoto K, Suzuki H, Kitagawa Y, Yamaguchi K, Yamada I, Hsien KJ, Tashiro E, Matsushita F, Ueda Y, Shikimori M, Fukuda H. Combined intra-arterial chemotherapy with TPP (THP-ADM, CDDP, PEP) for oral squamous cell carcinomas. Jpn J Oral Maxillofac Surg 1993;39:819–822.
Suzuki H, Hashimoto K, Kitagawa Y, Fukuda H. Clinical and histopathological effect of TPP (4′-O-tetrahydropyranyladriamycin, cis-platinum, peplomycin) intra-arterial induction chemotherapy for head and neck carcinomas. J Jpn Soc Cancer Ther 1993;28:920–928.
Author information
Authors and Affiliations
About this article
Cite this article
Tohnai, I., Ueda, M., Kaneda, T. et al. Primary clinical effects of PP therapy (cisplatin and peplomycin) and TPP therapy (4′-O-tetrahydropyranyladriamycin, cisplatin and peplomycin) for oral cancer. Int J Clin Oncol 1, 139–144 (1996). https://doi.org/10.1007/BF02348379
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02348379